Substitute Form PTO-1449 (Modified)

ment of Commerce nd Trademark Office Attorney's Docket No. 18202-033US1/1051US Application No. 09/463,542

List of Patents and Publications for Applicant's Information Disclosure Statement

Applicant Johan Auwerx et al.

Filing Date

Group Art Unit

| (37 CFR §1.98(b)) | | | | December 11, 2002 | | | 1636-1033 | |
|---------------------|--------------|--------------------|---------------------|--------------------|-------|----------|----------------------------|--|
| OF OF IC \$1.50 | | | | tent Documents | | | 1. Marric | |
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate | |
| ww | AA | 2004/0106135 | 06/03/04 | Mukherjee et al. | 435 | 6 | 09/06/03 | |
| 1 | AB | 2004/0019072 | 01/29/04 | Canan-Koch et al. | 514 | 290 | 02/05/03 | |
| | AC | 3,845,089 | 10/29/74 | Henrick | 554 | 220 | 07/27/72 | |
| | AD | 3,884,758 | 05/20/75 | Green | 435 | 34 | 01/30/74 | |
| | AE | 4,105,681 | 08/08/78 | Bollag et al. | 554 | 111 | 08/13/76 | |
| | AF | 4,193,931 | 03/18/80 | Loeliger | 514 | 510 | 04/24/78 | |
| | AG | 4,215,215 | 07/29/80 | Bollag et al. | 544 | 176 | 07/06/79 | |
| | AH | 4,534,979 | 08/13/85 | Love et al. | 514 | 529 | 11/02/84 | |
| | AI | 4,648,996 | 03/10/87 | Aig et al. | 554 | 103 | 06/20/85 | |
| | AJ | 4,783,549 | 12/08/88 | Lang et al. | 560 | 104 | 09/04/85 | |
| | AK | 4,833,254 | 05/23/89 | Berlin et al. | 548 | 454 | 05/11/87 | |
| | AL | 4,879,284 | 11/07/89 | Land et al. | 514 | 62 | 12/05/86 | |
| <u> </u> | AM | 4,892,940 | 01/09/90 | Maignan et al. | 536 | 55.2 | 05/22/87 | |
| | AN | 4,977,276 | 12/11/90 | Berlin et al. | 549 | 58 | 12/28/89 | |
| | AO | 5,130,333 | 07/14/92 | Pan et al. | 514 | 460 | 10/19/90 | |
| | AP | 5,198,567 | 03/30/93 | Lang et al. | 560 | 56 | 07/23/91 | |
| | AQ | 5,219,888 | 06/15/93 | Katocs, Jr. et al. | 514 | 560 | 03/31/92 | |
| | AR | 5,264,372 | 11/23/93 | Beaumont et al. | 436 | 504 | 03/15/91 | |
| | AS | 5,304,575 | 04/19/94 | Beck | 514 | 563 | 12/17/92 | |
| <u> </u> | AT | 5,441,971 | 08/15/95 | Sohda et al. | 514 | 342 | 10/12/93 | |
| | AU | 5,512,683 | 04/30/96 | Klaus et al. | 549 | 9 | 10/18/94 | |
| | AV | 5,654,338 | 08/05/97 | Metivier | 514 | 570 | 04/25/95 | |
| | AW | 5,700,836 | 12/23/97 | Klaus et al. | 514 | 544 | 10/21/96 | |
| | AX | 5,705,167 | 01/06/98 | Bernardon et al. | 424 | 401 | 04/26/95 | |
| | AY | 5,728,739 | 03/17/98 | Ailhaud et al. | 514 | 725 | 08/02/95 | |
| | AZ | 5,763,487 | 06/09/98 | Bernardon | 514 | 569 | 01/22/96 | |
| MM | BA | 5,968,908 | 10/19/99 | Epstein et al. | 514 | 42 | 11/14/95 | |

| Examiner Signature | Date Considered |
|--|--|
| 7/17 Marich | 11/9/05 |
| EXAMINER: Initial if citation considered, whether or not citation is in co | informance with MPEP 609; Draw line through citation if not in |
| conformance and not considered. Include copy of this form with next co | mmunication to applicant. |

AUG 2 5 2005 22

Substitute Form PTO-1449 (Modified)

U.S. Department of Commerce Patent and rademark Office

Attorney's Docket No. 18202-033US1/1051US Application No. 09/463,542

List of Patents and Publications for Applicant's Information Disclosure Statement

Applicant
Johan Auwerx et al.

Filing Date
December 11, 2002

Group Art Unit 1636- ルララ

(37 CFR §1.98(b))

| | | | | tent Documents | | | Filing Date |
|---------------------|--------------|--------------------|---------------------|----------------|-------------|-------------|----------------|
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | If Appropriate |
| MM | BB | 5,977,125 | 11/02/99 | Hibi et al. | 514 | 277 | 05/6/97 |
| WW | BC | 6,017,924 | 01/25/00 | Edwards et al. | 514 | 292 | 08/12/99 |
| MM | BD | 6,200,802 | 03/13/01 | Greene et al. | 435 | 325 | 10/08/93 |
| WW | BE | 6,534,516 | 03/18/03 | Edwards et al. | 514 | 285 | 11/24/99 |
| MM | BF | 6,815,168 | 11/09/04 | Greene et al. | 435 | 7.1 | 06/01/00 |

| Examiner | Desig. | Document | Publication | Published Foreign Pate Country or | | | Trans | slation |
|----------|--------|-------------|-------------|-----------------------------------|----------|----------|-------|---------|
| Initial | ID ID | Number | Date | Patent Office | Class | Subclass | Yes | |
| MW | BG | 0 305 890 | 03/08/89 | EP | | | | X+ |
| 1 | ВН | 0169571 | 01/29/86 | EP | | | | X+ |
| | BI | 0253393 | 01/20/88 | EP | | | | |
| | ВЈ | 0266992 | 05/11/88 | EP | | | | |
| | BK | 05 194 209A | 08/03/93 | ЛР | | | | X* |
| | BL | 0552624 | 07/28/97 | EP | • | 1 | | |
| | ВМ | 0568898 | 04/01/98 | EP | | / | | X+ |
| | BN | 0641759 | 12/09/98 | EP | | | | X+ |
| | во | 0679628 | 11/02/95 | EP | | | | X+ |
| | BP | 0698392 | 02/28/96 | ЕР | | | | X+ |
| | BQ | 0718285 | 06/26/96 | EP | | | | |
| | BR | 0859608 | 02/11/04 | EP | \perp | | | |
| | BS | 0873295 | 04/02/03 | EP | | | | |
| | вт | 1336600 | 08/20/03 | EP | | | | |
| | BU | 1426048 | 06/09/04 | EP . | | | | |
| | BV | 2188634 | 10/07/87 | UK | | | | |
| | BW | 2197316 | 05/18/88 | UK | | | | |
| | вх | 2390428 | 12/08/78 | FR | $\Box I$ | | | X+ |
| | BY | 2719041 | 10/27/95 | FR | Π | | | X+ |
| WW. | BZ | 2719042 | 10/27/95 | FR | \Box | | | X+ |

Examiner Signature W W Ch

Date Considered

11/9/05

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)

Department of nark Office Attorney's Docket No. 18202-033US1/1051US Application No. 09/463,542

List of Patents and Publications for Applicant's **Information Disclosure Statement**

Applicant Johan Auwerx et al.

Filing Date

December 11, 2002

Group Art Unit 1626 1633

| (37 CFR §1.9) | B(b)) | | | December 11, 20 | | 1 636 W | <u> </u> | |
|---------------|--------|----------|-------------|--------------------------------|-----------|----------------------|----------|----------|
| | | | | Published Foreign Paten | t Applica | tions | | |
| Examiner | Desig. | Document | Publication | Country or | 1 | | | slation |
| Initial | ID | Number | Date | Patent Office | Class | Subclass | /Yes | No |
| MM | CA | 2729664 | 07/26/96 | FR | | | <u>/</u> | X+ |
| | СВ | 2819213 | 09/24/87 | DE | | / | | X+ |
| | СС | 83/00930 | 03/17/83 | PCT | | | | |
| | CD | 89/04489 | 05/18/89 | PCT | | | | <u> </u> |
| | CE | 91/12258 | 08/22/91 | PCT | | | L | l |
| | CF | 93/09236 | 05/13/93 | PCT | | | | |
| | CG | 93/15740 | 08/19/93 | PCT | | | | |
| | СН | 93/21146 | 10/28/93 | PCT | | | | |
| | CI | 94/12880 | 06/09/94 | PCT | | | | |
| | CJ . | 94/15901 | 07/21/94 | PCT | | | | |
| | CK | 94/15902 | 07/21/94 | PCT | | | | |
| | CL | 94/17796 | 08/18/94 | PCT | | 17 | | |
| | CM | 95/04036 | 02/09/95 | PCT | | | | |
| | CN | 95/07694 | 03/23/95 | PCT | | | | |
| | СО | 95/07697 | 03/23/95 | PCT | | | | |
| | СР | 96/05165 | 02/22/96 | PCT | | | | |
| | CQ | 96/13478 | 05/09/96 | PCT | | | | X+ |
| | CR | 96/20913 | 07/11/96 | PCT | | | | |
| | CS | 97/10813 | 03/27/97 | PCT | $\top T$ | | | |
| | СТ | 97/12853 | 04/10/97 | PCT | TT | | | |
| | CU | 97/25042 | 07/17/97 | PCT | | | | |
| ww | CV | 97/33881 | 09/18/97 | PCT | 1 | | | |
| | 1 | | | | | | | |

X+= An English language equivalent is provided
X*= An English language Derwent abstract is provided

| | Other Documents (include Author, Title, Date, and Place of Publication) | | | | | |
|----------|---|---|--|--|--|--|
| Examiner | Desig. | | | | | |
| Initial | ID | Document | | | | |
| MAN | CW | Barnett et al., "Effect of clofibrate on glucose tolerance in maturity onset diabetes," British Journal of Clinical Pharmacology 4:455-458 (1977) | | | | |

| Examiner Signature | Date Considered |
|--|---|
| Willamich | 11/9/105 |
| EXAMINER: Initial if citation considered, whether or not citation is in co | nformance with MPEP 609; Draw line through citation if not in |
| conformance and not considered. Include conviol this form with next co | |

AUS 2 5 2005 C

Substitute Form PTO-1449 (Modified)

U.S. Departments Commerce Patent and Tablemark Office

Attorney's Docket No. 18202-033US1/1051US

Application No. 09/463,542

List of Patents and Publications for Applicant's Information Disclosure Statement

Applicant
Johan Auwerx et al.

Filing Date

Group Art Unit 1636— (133

(37 CFR §1.98(b))

December 11, 2002 1636

| (37 CFR 91.90 | \ <u>-11</u> | Other Documents (include Author, Title, Date, and Place of Publication) |
|---------------------|--------------|---|
| Examiner Initial | Desig. ID | Document |
| MM | сх | Berger et al., "Interaction of Glucocorticoid Analogues with the Human Glucocorticoid Receptor," J. Steroid. Biochem. Molec. Biol. 41: 733-738 (1992) |
| | CY | Boehm et al, "Synthesis and structure-activity relationships of novel retinoid X receptor-selective retinoids," J. of Medicinal Chemistry 37(18):2930-41 (1994) |
| | CZ | Broach, J.R., "The Yeast of Plasmid 2μ Circle," In: The Molecular Biology of the Yeast Saccharomyces: Life Cycle and Inheritance, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., pp. 445-470 (1981) |
| | DA | Carter S.K. et al.(Eds.) Chemotherapy of Cancer, 2nd edition, New York: John Wiley & Sons, Appendix C, pp.364-365 (1981) |
| | DB | Chater et al., "Streptomyces ØC31-Like Phages: Cloning Vectors, Genome Changes and Host Range," In: Sixth International Symposium on Actinomycetes Biology, Debrecen, Hungary, August 26-30, 1985, pp 45-54 (1986) |
| | DC | Chemical Abstracts Accession No. 123:281583 for Motojima, K, "Toward the treatment of obesity. Role of PPAR Gamma in Adipogenesis," Tanpakushitsu Kakusan Koso 40(13):1936-1941 (1995). |
| | DD | Crombie et al., "Creatine kinase activity as an indicator of unopposed estrogen action in the mouse uterus associated with anti-progesterone treatment." J. Steroid Biochem Mol Biol. 49(2-3)123-9 (1994) |
| | DE | Derwent Abstract for JP 05 194 209A, published 08/03/93, entitled "Vascular endothelial cell function improvers – contains fenofibrate e.g. isopropyl 2-(p-(p-chloro:benzoyl)phenoxy)-2-methyl propionate" |
| | DF | Dreborg et al., "The chemistry and standardization of allergens," Chapter 10 in the Handbook of Experimental Immunology, 4th Ed., D.M. Weir et al. (Ed.), Oxford; Boston: Blackwell Scientific Publications, pp. 10.1-10.27(1986) |
| | DG | Giguere et al., "Functional Domains of the Human Glucocorticoid Receptor," Cell 46:645-652 |
| | DH | Giguere et al., "Identification of a receptor for the morphogen retinoic acid," Nature 330(2):624-629 (1987) |
| | DI | Grundy et al., "Metabolic and Health Complications of Obesity," Disease-a-Month 36(12):645-696 (1990) |
| | DJ | Gryczan, T.J., "Molecular Cloning in <i>Bacillus subtilis</i> ," In: The Molecular Biology of the Bacilli, New York: Academic Press, Inc., pp.307-329 (1982) |
| | DK | Ibrahimi et al., "Evidence for a Common Mechanism of Action for Fatty Acids and Thiazolidinedione Antidiabetic Agents on Gene Expression in Preadipose Cells," Molecular Pharmacology 46:1070-1076 (1994) |
| | DL | Jow, L. and R. Mukherjee, "The human peroxisome proliferator-activated receptor (PPAR) subtype NUC1represses the activation of hPPARα and thyroid hormone receptors," .J Biol Chem. 270(8):3836-40 (1995) |
| | DM | Karam, J., "Type II Diabetes and Syndrome X," Endocrinology and Metabolism Clinics of North America 21(2): 329-350 (1992) |
| | DN | Kawamatsu et al., "Studies on Antihyperlipidemic Agents," Arzneim-Forsch 30: 454-459 (1980) |
| WW | DO | Lenhard et al., "Analysis of Thiazolidinedione, Biguanide and Retinoid Effects on Adipogenesis and the Nuclear Receptors PPARy and RXR," Diabetologia, Supplement 39(5): A234 (1996) |

| Examiner Signature WWW.CM | Date Considered |
|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in considered, and not considered, include conv. of this form with next considered. | onformance with MPEP 609; Draw line through citation if not in |

Substitute Form PTO-1449 (Modified)

of Commerce .S. Departme demark Office

Attorney's Docket No. 18202-033US1/1051US Application No. 09/463,542

List of Patents and Publications for Applicant's Information Disclosure Statement

Applicant Johan Auwerx et al.

Filing Date December 11, 2002 **Group Art Unit** 1636-1633

Other Documents (include Author, Title, Date, and Place of Publication) (37 CFR §1.98(b))

| 37 CFR §1.98 | (b)) | Other Documents (include Author, Title, Date, and Place of Publication) |
|--------------|--------------|--|
| Examiner | Desig. | Downsont |
| Initial ID | | Mangelsdorf et al., "A Direct Repeat in the Cellular Retinol-Binding Protein Type II Gene Confers |
| MAINO DP | | Mangelsdorf et al., "A Direct Repeat in the Centular National States of Centular National |
| MW | | Differential Regulation by RXR and RAR, "Cell 66.333-361 (1931) Mangelsdorf et al., "Nuclear receptor that identifies a novel retinoic acid response pathway," Nature |
| | DQ | Mangelsdorf et al., Nuclear receptor that re- |
| | | 345:224-229 (1990) Maniatis, T., "Recombinant DNA Procedures in the Study of Eukaryotic Genes," In: Cell Biology: Maniatis, T., "Recombinant DNA Procedures in the Study of Eukaryotic Genes," In: Cell Biology: |
| | | Maniatis, T., "Recombinant DNA Procedures in the Study of Editaryons Series," A Comprehensive Treatise, Vol. 3, Gene Sequence Expression, New York: Academic Press, |
| 1 | DR | pp. 563-608 (1980) |
| | } | |
| 1 | DS | Miller et al., "An Insect Baculovirus Host-Vector System for High-Bove Englished Genes," In: Genetic Engineering: Principles and Methods, Setlow, J. K. et al. (Eds.), New York: |
| 1 | פט | Plenum Press, Vol. 8, pp. 277-297 (1986) |
| | | Television of the treatment of openicy. Kole of Francounting in the programme in the progra |
| 1 | DT | Motojima, K, [Toward the treatment of observed the strong of the estrogen responsive to one strand of the estrogen responsive |
| | + | Muchariee R "Selective binding of the estrogen receptor to one strain of |
| 1 | DU | element," Nucleic Acids Res. 21(11):2655-2661 (1993) |
| | DV | Nestel P.I. "Effects of N-3 fatty acids on lipid metabolish, Alli. Nov. 14dd. |
| | | Ptashne, M., "How eukaryotic transcriptional activators work," Nature 335:683-689 (1988) |
| } | DW | Plasmie, IVI., Trow cural your management of the |
| . 1 | | Rigas et al., "Lipoprotein alterations in patients treated with novel retinoids," Proceeding of the American Association for Cancer Research, 86th Annual Meeting, Toronto, Ontario, Canada, March |
| | DX | American Association for Cancer Research, so Alliuar Meeting, Totalic, |
| <u> </u> | 1 | 18-22, 1995, Volume 36, p.506 (March, 1995) Römpp Chemie Lexikon, 9th Extended and Revised Edition, S., Falbe, J. et al. (Eds.) Georg Thiemed Roman Chemies (1992) (1992) (Pages in German) |
| | DY | Römpp Chemie Lexikon, 9th Extended and Revised Edition, 9th 12 2005 3856 (1992) [Pages in German] |
| ļ <u>ļ</u> | | Verlag Stuggart: New York, pp. 3855-3856 (1992) [Pages in German] Safonova et al., "Fatty Acids and Retinoids Act Synergistically on Adipose Cell Differentiation," |
| | DZ | Safonova et al., "Fatty Acids and Retinious Act of Safono |
| | | Biochem Biophys Res Commun. 204(2):498-504 (1994) St. Groth et al., "Production of Monoclonal Antibodies: Strategy and Tactics," J. Immunol. Method |
| į | EA | St. Groth et al., Production of Monocolonia American |
| L | | 35:1-21(1980) Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed. Volume A8: Coronary Therapeutics to Ullmann's Encyclopedia of Industrial Chemistry, 5th Ed. Volume A8: Coronary Therapeutics to |
|] [| ED | Ullmann's Encyclopedia of Industrial Chemistry, 3th Ed. Volume Ad. Cotomby Display Technology, Gerhartz, W. et al. (Eds.) VCH: Weinheim, Federal Republic of Germany), pp |
| 1 1 . | EB | 308-314 (1987) |
| | | Limesono et al "Retinoic acid and thyroid hormone induce gene expression through a common t |
| 1 1 | EC | |
| | | Wy GV and CH Wil "Receptor-mediated in vitro Gene Transformation of |
| | ED | Carrier-System," J. Biol. Chem. 262: 4429-4432 (1987) |
| | | |
| | EE | responsive Element of the Rat Hydratase-Denydrogenase Gene, Journal of Land |
| | | |
| 40.00 | PE | Zhang et al., "Positional cloning of the mouse <i>obese</i> gene and its human homologue," Nature |
| MW | EF | 372(6505):425-432 (1994) |

| Examiner Signature | Date Considered U1 9 105 |
|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in c | onformance with MPEP 609; Draw line through citation if not in |
| EXAMINER: Initial if citation considered, whether or not classes a most considered, whether or not classes a minimum of the converted to the c | ommunication to applicant. |

conformance and not considered. Include copy of this form with next communication to applicant.

| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | | | | | | | | |
|--|--|--------------------|------------------|-------------------------------|-------|---|----------------------------|--|
| | List of Patents and Publications for Applicant's Information Disclosure Statement (37 CFR §1.98(b)) | | | Applicant Johan Auwerx et al. | | JUN 2 0 2005 | | |
| (37 CFR §1.98 | | | | Filing Date December 11, 20 | 002. | Group Art Uni 1 636 \ \(L32 | TRADEWARK | |
| | , | | | t Documents | | Μ. | Marvich | |
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate | |
| WW | AA | 2002/0144302 | 10/03/02 | Mahfoudl | 800 | 21 | 11/06/97 | |
| | AB | 2002/0193291 | 12/19/02 | Heyman et al. | 514 | 3 | 05/07/01 | |
| | AC | 2003/0104975 | 06/05/03 | Auwerx et al. | 514 | 1 | 06/14/02 | |
| | AD | 2004/0019090 | 01/29/04 | Brooks et al. | 514 | 365 | 05/07/03 | |
| | AE | 2004/0082623 | 04/29/04 | Rochhi et al. | 514 | 357 | 06/28/01 | |
| | AF | 2004/0171689 | 09/02/04 | Desreumaux et al. | 514 | 559 | 04/04/02 | |
| | AG | 4,945,050 | 07/31/90 | Sanford et al. | 435 | 459 | 11/13/84 | |
| | AH | 5,498,696 | 03/12/96 | Briggs et al. | 530 | 350 | 05/13/93 | |
| | AI | 5,527,690 | 06/18/96 | Goldstein et al. | 435 | 69.1 | 10/01/93 | |
| | AJ | 5,683,880 | 11/04/97 | Kamb | 435 | 6 | 07/07/95 | |
| | AK | 5,686,596 | 11/11/97 | Mukherjee | 536 | 23.5 | 06/02/95 | |
| | AL | 5,707,803 | 01/13/98 | Lamb et al. | 435 | 6 | 03/27/95 | |
| | AM | 5,726,041 | 03/10/98 | Chrespi et al. | 435 | 69.1 | 08/22/96 | |
| | AN | 5,780,676 | 07/14/98 | Boehm et al. | 562 | 490 | 06/07/95 | |
| | AO | 5,814,517 | 09/29/98 | Seidel et al. | 435 | 325 | 03/27/95 | |
| | AP | 5,891,631 | 04/06/99 | Goldstein et al. | 435 | 6 | 06/14/96 | |
| | AQ | 5,962,731 | 10/05/99 | Boehm et al. | 562 | 460 | 06/07/95 | |
| | AR | 5,972,881 | 10/26/99 | Heyman et al. | 514 | 3 | 11/26/97 | |
| | AS | 6,028,052 | 02/22/00 | Heyman et al. | 514 | 3 | 09/17/96 | |
| | AT | 6,043,279 | 03/28/00 | Boehm et al. | 514 | 568 | 02/12/97 | |
| | AU | 6,068,976 | 05/30/00 | Briggs et al. | 435 | 6 | 03/19/96 | |
| | AV | 6,228,862 | 05/08/01 | Heyman et al. | 514 | 277 | 05/11/99 | |
| | AW | 6,316,404 | 11/13/01 | Heyman et al. | 514 | 3 | 12/22/00 | |
| | AX | 6,320,074 | 11/20/01 | Boehm et al. | 562 | 490 | 10/27/98 | |
| | AY | 6,417,212 | 07/09/02 | Brooks et al. | 514 | 374 | 08/23/00 | |
| | AZ | 6,521,633 | 02/18/03 | Heyman et al. | 514 | 277 | 05/07/01 | |
| mm | ВА | 6,545,049 | 04/08/03 | Canan-Koch et al. | 514 | 569 | 09/02/99 | |

| Examiner Signature WMWWich | Date Considered U/9/05 |
|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance and not considered, include copy of this form with past conformance. | informance with MPEP 609; Draw line through citation if not in |

| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office List of Patents and Publications for Applicant's Information Disclosure Statement | | | | | Application No. 09/463,54 | | |
|---|--------------|--------------------|------------------------|----------------------------|---------------------------|----------------------------|----------------------------|
| | | | Applicant Johan Auwerx | et al. | | JUN 2 11 200 | |
| (37 CFR §1.98 | B(b)) | | | Filing Date December 11, 2 | 2002 | Group Art Uni 1636-1 (1 | |
| | | | U.S. Paten | t Documents | | | |
| Examiner Initial | Desig. ID | Document Number | Publication Date | Patentee | Class | Subclass | Filing Date If Appropriate |
| MM | ВВ | 6,593,493 | 07/15/03 | Ardecky et al. | 562 | 465 | 09/14/00 |
| WW | ВС | 6,610,696 | 08/26/03 | Brooks et al. | 514 | 256 | 04/11/02 |
| WW | BD | 6,610,883 | 08/26/03 | Brooks et al. | 562 | 490 | 07/13/98 |
| Ww | BE | 6,825,222 | 11/30/04 | Brooks et al. | 514 | 365 | 05/07/03 |

| Foreign Patent Documents or Published Foreign Patent Applications | | | | | | | | |
|---|--------|-----------|-------------|---------------|--|---------------|-------|-------------|
| Examiner Initial | Desig. | Document | Publication | Country or | | | Trans | lation |
| | ID | Number | Date | Patent Office | Class | Subclass | Yes | No |
| VWW | BF | 0 139 417 | 07/26/89 | EP | | | | |
| | BG | 0 569 237 | 11/10/93 | EP | | \mathcal{I} | | |
| | вн | 02/00611 | 01/03/02 | PCT | | | | |
| | BI | 02/094877 | 11/28/02 | PCT | | | | |
| | BJ | 91/01384 | 02/07/91 | PCT | | | | |
| | ВК | 92/20642 | 11/26/92 | PCT | | j | | |
| | BL | 94/18959 | 09/01/94 | PCT | | j | | |
| | ВМ | 95/11974 | 05/04/95 | PCT | | 1 | | |
| | BN | 95/23225 | 08/31/95 | PCT | 1 | 1 | | |
| | во | 96/01430 | 01/18/96 | PCT | | 1 | | |
| | BP | 96/23884 | 08/08/96 | PCT | | 1 | | |
| | BQ | 96/29405 | 09/26/96 | PCT | | <i>j</i> | | <u>_</u> |
| | BR | 97/10819 | 03/27/97 | PCT | | | | |
| | BS | 98/05331 | 02/12/98 | PCT | | | | |
| | вт | 98/21349 | 05/22/98 | PCT | | | | |
| | BU | 98/43081 | 10/01/98 | PCT | 1 / | | | |
| | BV | 99/05161 | 02/04/99 | PCT | 1 / | | | |
| MIN | вw | 99/51740 | 10/14/99 | PCT | 1 1 | | | |

Other Documents (include Author, Title, Date, and Place of Publication)

| Examiner Signature WMM JJ Ch | Date Considered ((/ 9 / 05 | | | | | | |
|---|-----------------------------|--|--|--|--|--|--|
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | | |

Application No. U.S. Department of Commerce Attorney's Docket No. Substitute Form PTO-1449 Patent and Trademark Office (Modified) 18202-033US1/1051US 09/463,542 OTPE Applicant List of Patents and Publications for Applicant's JUN 2 0 2005 Johan Auwerx et al. Information Disclosure Statement Group Art Unit Filing Date December 11, 2002 1636-163 (37 CFR §1.98(b)) Examiner Desig. Initial ID Document Amri et al., "Regulation of adipose cell differentiation. I. Fatty acids are inducers of the aP2 gene BXMM expression," J. Lipid Research 32:1449-1456 (1991) Amri et al., "Regulation of adipose cell differentiation. II. Kinetics of induction of the aP2 gene by BY fatty acids and modulation by dexamethasone," J. Lipid Res. 32: 1457-1463 (1991) Aperlo et al., "cDNA cloning and characterization of the transcriptional activities of the hamster BZ peroxisome proliferators-activated receptor haPPARy," Gene 162: 297-302 (1995) Aubert et al., "Evidence for a novel regulatory pathway activated by (carba)prostacyclin in CA preadipose and adipose cells," FEBS Letters 397: 117-121 (1996) Auwerx et al., "Transcription, adipocyte differentiation, and obesity," J. Mol. Med. 74: 347-352 CB Auwerx et al., "Transcriptional control of triglyceride metabolism: fibrates and fatty acids change CC the expression of the LP1 and apo C-III genes by activating the nuclear receptor PPAR," Atherosclerosis 124(Suppl.): S29-S37 (1996) Belluzi et al., "Effect of an enteric-coated fish-oil preparationon on relapses in crohn's disease," N. CD Engl. J. Med. 334: 1557-1560 (1996) Berger et al., "Thiazolidinediones produce a conformational change in peroxisomal proliferators-CE activated receptor-y: binding and activation correlate with antidiabetic actions in db/db mice," Endocrinology 137: 4189-4195 (1996) Brandes et al., "Adipocyte conversion of cultured 3T3-L1 preadipocytes by bezafibrate," Life CF Sciences 40: 935-941 (1987) Brinster et al., "Factors affecting the efficiency of introducing foreign DNA into mice by CG microinjecting eggs," Proc. Nat. Acad. Sci. USA 82: 4438-4442 (1985) Brun et al., "Differential activation of adipogenesis by multiple PPAR isoforms," Genes & CH Development 10: 974-984 (1996) Bunin, B.A. and J.A. Ellman, "A general and expedient method for the solid-phase synthesis of 1,4 CI benzodiazepine derivatives," J. Am. Chem. Soc. 114:10997-10998 (1992) Capecchi, M.R., "High efficiency transformation by direct microinjection of DNA into cultured CJ mammalian cells," Cell 22:479-488 (1980) Capecchi, M.R., "Altering the genome by homologous recombination," Science 244: 1288-1292 CK (1989)Cech, T.R., "Ribozymes and their medical implications," J. Am. Med. Assoc. 260:3030-3034 (1988) CL Chawla, A. and M.A. Lazar, "Peroxisome proliferators and retinoid signaling pathways co-regulate CM preadipocyte phenotype and survival," Proc. Natl. Acad. Sci. U.S.A. 91: 1786-1790 (1994) Chen C. and H. Okayama, "High-Efficiency Transformation of Mammalian Cells by Plasmid CN DNA," Mol. Cell Biol. 7:2745-2752 (1987) Chen et al., "Identification of two mPPAR related receptors and evidence for the existence of five CO subfamily members," Biochemical and Biophysical Research Communications 196:671-677 (1993) Christy et al., "Differentiation-induced gene expression in 3T3-L1 preadipocytes: CCAAT/enhancer CP binding protein interacts with and activates the promoters of two adipocyte-specific genes," Genes & Development 3: 1323-1335 (1989) Chu et al., "Electroporation for the efficient transfection of mammalian cells with DNA,"Nucleic

| Examiner Signature MMM Ch | Date Considered |
|--|--|
| | |
| EXAMINER: Initial if citation considered, whether or not citation is in co | informance with MPEP 609; Draw line through citation if not in |
| conformance and not considered, Include conv. of this form with next co | mmunication to applicant |

Cornelius et al., "Regulation of adipocyte development," Annu. Rev. Nutr. 14: 99-129 (1994)

CO

CR

MM

Acids Res. 15:1311-1326 (1987)

| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | | | Attorney's Docket No. 18202-033US1/1051US | Application No. 09/463,542 | SIPE. | |
|--|--------------|---|---|----------------------------|--------------|--|
| | | d Publications for Applicant's n Disclosure Statement | Applicant Jun 2 0 2008 Johan Auwerx et al. | | | |
| | | | Filing Date | Group Art Unit | TRADEMAR | |
| (37 CFR §1.98 | | | December 11, 2002 | 1636-1635 | PRADEMA | |
| | | ocuments (include Author, | <u> Fitle, Date, and Place o</u> | f Publication | 1) | |
| Examiner Initial | Desig. ID | | Document | | | |
| MM | CS | Cristiano et al., "Hepatic gene therapy and expression in primary hepatocytes | s," Proc. Natl. Acad. Sci. USA 9 | 0:2122-2126 (19 | 93) | |
| | СТ | Curiel et al., "Gene transfer to respira pathway," Am. J. Respir. Cell. Mol. E | Biol. 6:247-252 (1992) | | · | |
| | CU | Davidson et al., "A model system for adenoviral vector," Nature Genetics 3 | | ntral nervous syst | em using an | |
| | cv | De Vos et al., "Thiazolidinediones reperoxisome proliferator-activated rece | | | of | |
| | cw | De Vos et al., "Induction of ob gene e loss and reduced food intake," J Biol | expression by corticosteroids is a | ccompanied by b | ody weight | |
| | СХ | De Vos et al., "Glucocorticoids induci mechanism of transcriptional activation | e the expression of the leptin ger | ne through a non- | classical | |
| | CY | Desreumaux et al., "Attenuation of co (RXR)/peroxisome proliferator-activa therapeutic strategies," J Exp Med. 19 | lon inflammation through activated receptor γ (PPARγ) heterodicated | ators of the retino | | |
| | CZ | Desvergne, B. and W. Wahli, "PPAR in <i>Inducible Gene Expressio, Volume</i> Boston: Birkhäuser. 1: 142-176 (1995) | a key nuclear factor in nutrient 1: Environmental Stresses and 1 | | | |
| | DA | Devchand et al., "The PPARα-leukotriene B ₄ , pathway to inflammation control," Nature 384: 39-43 (1996) | | | | |
| | DB | Dreyer et al., "Control of the perxisomal β-oxidation pathway by a novel family of nuclear hormone receptors," Cell 68: 879-887 (1992) | | | | |
| | DC | Elbrecht et al., "Molecular cloning, expression and characterization of human peroxisome proliferators activated receptors γ1 and γ2," Biochem. Biophys. Res. Commun. 224: 431-437 (1996) | | | | |
| | DD | Fajas et al., "The organization, promo Biol. Chem. 272:18779-18789 (1997) | ter analysis, and expression of the | he human PPARy | gene," J. | |
| | DE | Fajas et al., "Regulation of peroxisome proliferator-activated receptor γ expression by adipocyte differentiation and determination factor 1/sterol regulatory element binding protein 1: Implications for adipocyte differentiation and metabolism," Mol Cell Biol. 19(8):5495-5503 (1999) | | | | |
| | DF | Felgner, P.L. and G.M. Ringold, "Cationic liposome-mediated transfection," Nature 337:387-388 (1989) | | | | |
| | DG | Felgner et al., "Lipofection: A highly efficient, lipid-mediated DNA-transfection procedure," Proc. Natl. Acad. Sci. USA. 84:7413-7417 (1987) | | | | |
| | DH | Ferrari et al., "An in vivo model of so immunodeficiency," Science 251:136 | matic cell gene therapy for hum | an severe combin | ed | |
| | DI | Fingl, E. and D.M. Woodbury, "Gene Therapeutics, Goodman et al. (Eds.) N | ral Principles," Chapter 1 in The | | | |
| | DJ | Flier, J. S., "The adipocyte: storage de 15-18 (1995) | | | | |
| | DK | Forman et al., "15-Deoxy-Δ ^{12,14} -Prost PPARy," Cell 83: 803-812 (1995) | aglandin J_2 is a ligand for the ad | ipocyte determina | ation factor | |
| ww | DL | Freytag, S. and T.J. Geddes, "Recipro | cal regulation of adipogenesis b | y Myc and C/EBI | Pa," Science | |

| Examiner Signature | Date Considered | | | | | |
|---|---------------------------|--|--|--|--|--|
| M:Men rid | 11 /9/05 | | | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | | | | |
| conformance and not considered. Include copy of this form with next co | mmunication to applicant. | | | | | |

| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | | | • | Attorney's Docket No. 18202-033US1/1051US | Application No. 09/463,542 | | |
|---|---|--------------|--|--|---------------------------------|--|--|
| Lis | | | d Publications for Applicant's n Disclosure Statement | Applicant Jun 2 0 20 Johan Auwerx et al. | | | |
| | | | | Filing Date | Group Art Unit | | |
| (37 CF | R §1.98 | | | December 11, 2002 | CCN1 -060T | | |
| | | | ocuments (include Author, l | <u> Fitle, Date, and Place o</u> | f Publication) | | |
| Exam Init | | Desig. ID | | Document | | | |
| MN | Λ | DM | Freytag et al., "Ectopic expression of adipogenic program in a variety of mo (1994) | ouse fibroblastic cells," Genes & | Development 8: 1654-1663 | | |
| | | DN | Fried, M.G. and D.M. Crothers, "CAF binding stoichiometry and long range | effects," Nucl. Acids Res. 11:14 | 11-158 (1983) | | |
| | | DO | Gaillard et al., "Requirement and role Biochem. J. 257: 389-397 (1989) | | | | |
| | | DP | Gearing et al., "Structure of the mouse 255-263 (1994) | - | | | |
| | | DQ | Gharbi-Chibi et al., "Increase of adipo preadipocytes: requirements for thyro | | | | |
| | | DR | Giovanucci, E. and W.C. Willet, "Die (1994) | • | | | |
| | | DS | Goring et al., "In Situ detection of β-g Crystallin/lacZ gene," Science 235:45 | | enic mice with a γ- | | |
| | | DT | Göttlicher et al., "Fatty acids activate glucocorticoid receptor," Proc. Natl.A | | | | |
| | | DU | Green, S., "PPAR: a mediator of pero (1995) | xisome proliferator action," Mu | tation Research 333: 101-109 | | |
| | | DV | Greene et al., "Isolation of the human expression in hematopoietic cells and | | | | |
| | | DW | Hallakou et al., "Pioglitazone induces Diabetes 46(9):1393-1399 (1997) | | | | |
| | | DX | Hambor et al., "Functional consequen expression in a human T cell clone," J | | | | |
| | | DY | Hammer et al., "Spontaneous inflamm human β2m: An animal model of HLA | | | | |
| | | DZ | Hertz et al., "Thyromimetic mode of a gene transcription," Biochem. J. 319: | | rs: activation of malic' enzyme | | |
| | | EA | Ho et al., "Site-directed mutagenesis & Gene 77:51-59 (1989) | by overlap extension using the p | olymerase chain reaction," | | |
| | | EB | Houdebine, L.M. and D. Chourrout, "Transgenesis in fish," Experientia 47: 891-897 (1991) | | | | |
| | | EC | Hu et al., "Transdifferentiation of myo C/EBPα," Proc. Natl. Acad. Sci. U.S | | ription factors PPARy and | | |
| | | ED | Hulin et al., "The glitazone family of (1996) | antidiabetic agents," Current Ph | _ | | |
| | | EE | Isseman, I. and S. Green, "Activation peroxisome proliferators," Nature 347 | | none receptor superfamily by | | |
| | | EF | Joyner et al., "Production of a mutation embryonic stem cells," Nature 338:15 | on in mouse En-2 gene by homol | logous recombination in | | |
| MM | Kim I B and B M Spiegelman "ADDI/SPERRI promotes adiposed differentiation and and | | | | | | |

| Examiner Signature | Date Considered | | | | | |
|--|-----------------|--|--|--|--|--|
| Mynni ch | 11 (9 105 | | | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant | | | | | | |

| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | | | Attorney's Docket No. 18202-033US1/1051US | Application No. 0196 | | |
|---|--------|--|---|---|--|--|
| | | d Publications for Applicant's n Disclosure Statement | Applicant Johan Auwerx et al. | JUN 2 0 Z005 | | |
| | | | Filing Date December 11, 2002 | Group Art Unit 1784DEMAN | | |
| (37 CFR §1.9 | | ocuments (include Author, | | | | |
| Examiner | Desig. | | inte, Date, and Flace o | rubilcation) | | |
| Initial | ID | | Document | | | |
| WW | ЕН | Kliewer et al., "Differential expression proliferators-activated receptors," Pro | c. Natl. Acad. Sci. USA 91: 735 | 5-7359 (1994) | | |
| | EI | Kliewer et al., "A prostaglandin J ₂ me and promotes adipocyte differentiation | n," Cell 83: 813-819 (1995) | ferators-activated receptor γ | | |
| | EJ | Le Gal La Salle et al., Science 259:98 | 8 | | | |
| | EK | Lambe, K.G. and J.D. Tugwood, "A h by inducers of adipogenesis, including | | | | |
| | EL | Lefebvre et al., "Regulation of lipoprodistinct but complementary mechanism 17(9):1756-1764 (1997) | otein metabolism by thiazolidine | diones occurs through a | | |
| | EM | Le Gal La Salle et al., "An adenovirus Science 259: 988-990 (1993) | s vector for gene transfer into ne | urons and glia in the brain," | | |
| | EN | Lehmann et al., "An antidiabetic thiaz Proliferator-Activated Receptor y (PP | | | | |
| | EO | Leid et al., "Purification, cloning, and heterodimerizes to bind target sequence | RXR identity of the HeLa cell i | factor with which RAR or TR | | |
| | EP | Lemberger et al., "Expression of the p by stress and follows a diurnal rhythm | eroxisome proliferators-activate | ed receptor a gene is stimulated | | |
| | EQ | Lin F. and M.D. Lane, "Antisense CC gene expression and triglyceride accur Genes & Development 6:533-544 (19) | AAT/enhancer-binding protein mulation during differentiation of | RNA suppresses coordinate | | |
| | ER | Mansén et al., "Expression of the peroxisome proliferators-activated receptor (PPAR) in the mous colonic mucosa," Biochem. Biophys. Res. Commun. 222: 844-851 (1996) | | | | |
| | ES | Marcus-Sekura, C.J., "Techniques for expression," Anal. Biochem. 172:289 | using antisense oligodeoxyribor | nucleotides to study gene | | |
| | ET | Miard et al., "Atypical transcriptional Metab. Disord. 29(Suppl 1):S10-S12 (| regulators and cofactors of PPA | Ry," Int. J. Obes. Relat. | | |
| | EU | Miller et al., "The adipocyte specific transcription factor C/EBPα modulates human ob gene expression," Proc. Natl. Acad. Sci. U S A. 93(11):5507-5511 (1996) | | | | |
| | EV | Miller et al., "Human gene therapy co | mes of age," Nature 357:455-46 | 0 (1992) | | |
| | EW | Moller, D. E., and J.S. Flier, "Insulin New England Journal of Medicine 32: | resistance-mechanisms, syndror 5: 938-948 (1991) | nes, and implications," | | |
| | EX | Mukherjee et al., "Identification, chare Proliferator-Activated Receptor (PPA) Retinoid X Receptor Agonists and An | acterization, and tissue distributi R) isoforms PPARy2 versus PP/ tagonists," J. Biol. Chem. 272: 8 | ARy1 and activation with 8071-8076 (1997) | | |
| | EY | Mukherjee et al., "Human and rat perc similar tissue distribution to PPAR act | oxisome proliferators activated r tivators," J. Steroid Biochem. 51 | eceptors (PPARs) demonstrate (3/4): 157-166 (1994) | | |
| | EZ | Mulligan, R.C., "The basic science of | gene therapy," Science 260:926 | -931 (1993). | | |
| WM | FA | Nagy et al., "Oxidized LDL regulates | macrophage gene expression thi | rough ligand activation of | | |

| Examiner Signature Anna A | Date Considered | | | | | |
|---|--|--|--|--|--|--|
| Examiner Signature MMW Ch | 119105 | | | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in co | informance with MPEP 609; Draw line through citation if not in | | | | | |
| conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | |

| Substitute Form PTO-1449 (Modified) U.S. Department of Commerce Patent and Trademark Office | | Attorney's Docket No. 18202-033US1/1051US | Application No. 09/463,542 | | | |
|---|--------------|---|--|---|--|--|
| | | d Publications for Applicant's n Disclosure Statement | Applicant Johan Auwerx et al. | JUN 2 0 2005 | | |
| (37 CFR §1.98 | 3(b)) | | Filing Date December 11, 2002 | Group Art Unit 2 | | |
| | | ocuments (include Author, 1 | litle, Date, and Place of | f Publication) MADEWAY | | |
| Examiner Initial | Desig. ID | | Document | | | |
| 1/44/ | FB | Négrel et al., "Prostacyclin as a potent 399-405 (1989) | | | | |
| · | FC | Osborne et al., "5' end of HMG CoA mediated inhibition of transcription," | Cell 42:203- 212 (1985) | - | | |
| | FD | Osumi et al., "Two cis-acting regulate enhancer region of rat acyl-CoA oxida | ase gene," Biophys. Res. Commi | un. 175:866-871 (1991) | | |
| | FE | Oxender et al., "Attentuation in the Esstructure involving the tryptophan cod | Ion region," Proc. Natl. Acad. So | i. USA 76:5524-5528 (1979) | | |
| | FF | Price et al., "Lineage analysis in the v transfer," Proc. Natl. Acad. Sci. USA | 84:156-160 (1987) | | | |
| | FG | Pursel et al., "Genetic engineering of | livestock," Science 244:1281-12 | 88 (1989) | | |
| | FH | Quantin et al., "Adenovirus as an expression vector in muscle cells in vivo," Proc. Natl. Acad. Sci. USA 89:2581-2584 (1992) | | | | |
| | FI . | Quon et al., "Transfection of DNA into isolated rat adipose cells by electroporation," Biochem. Biophys. Res. Comm. 194: 338-346 (1993) | | | | |
| | FJ | Ren et al., "Peroxisome proliferators-activated receptor α inhibits hepatic S14 gene transcription," J. Biol.Chem.271:17167-17173 (1996) | | | | |
| | FK | Ricote et al., "Expression of the peroxisome proliferators-activated receptor γ (PPARγ) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein," Proc Natl Acad Sci USA 95(13): 7614-7619 (1988) | | | | |
| | FL | Sakai et al., "Sterol-regulated release of SREBP-2 from cell membranes requires two sequential cleavages, one within a transmembrane segment," Cell 85: 1037-1046 (1996) | | | | |
| | FM | Saladin et al., "Differential regulation of peroxisome proliferator activated receptor γ1 (PPARγ1) and PPARγ2 messenger RNA expression in the early stages of adipogenesis," Cell Growth Differ. 10(1):43-48 (1999) | | | | |
| | FN | Saladin et al., "Regulation of <i>ob</i> gene 638-641 (1996) | | , , | | |
| | FO | Saladin et al., "Transient increase in <i>obese</i> gene expression after food intake or insulin administration," Nature 377: 527-529 (1995) | | | | |
| | FP | Saltiel, A. R. and J.M. Olefsky, "Thiazolidinediones in the treatment of insulin resistance and type Il diabetes," Diabetes 45: 1661-1669 (1996) | | | | |
| | FQ | Schmidt et al., "Identification of a new activated by a peroxisome proliferator | s and fatty acids," Mol. Endocri | nol. 6:1634-1641 (1992) | | |
| | FR | Schoonjans et al., "Induction of LPL gelement and is independent of the pres | sence of multiple E boxes," J Mo | ol Biol. 304(3):323-34 (2000) | | |
| | FS | Schoonjans et al., "Role of the peroxis effects of fibrates and fatty acids on ge | some proliferators-activated rece ene expression," J. Lipid Res. 37 | ptor (PPAR) in mediating the 2: 907-925 (1996) | | |
| | FT | Schoonjans et al., "PPARa and PPARy activators direct a distinct tissue-specific transcriptional response via a PPRE in the lipoprotein lipase gene," The EMBO Journal 15: 5336-5348 (1996) | | | | |
| WW FU Schoonjans et al., "Acyl-CoA synthetase mRNA expression is controlled byfibric-acid derivative feeding and liver proliferation," Eur. J. Biochem. 216: 615-622 (1993) | | | | led byfibric-acid derivatives, | | |

| Examiner Signature | Date Considered | | | | | |
|---|-----------------|--|--|--|--|--|
| νν/οι αρρά Ολ | 11/9/05 | | | | | |
| EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in | | | | | | |
| conformance and not considered. Include copy of this form with next communication to applicant. | | | | | | |

| Substitute Form PTO-1449 (Modified) | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 18202-033US1/1051US | Application No. 09/463,542 | | |
|---|---|--|--|----------------------------|--|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement | | | Applicant Johan Auwerx et al. JUN 2 0 2005 | | | |
| (37 CFR §1.98(b)) | | | Filing Date December 11, 2002 | Group Art Unit | | |
| | Other D | ocuments (include Author, 1 | litle, Date, and Place of | f Publication) | | |
| Examiner Initial | Desig. ID | Document | | | | |
| ΜW | FV | Schoonjans et al., "Induction of the acyl-coenzyme A synthetase gene by fibrates and fatty acids is mediated by a peroxisome proliferators response element in the C promoter," J. Biol. Chem. 270: 19269-19276 (1995) | | | | |
| | FW | Schoonjans et al., "The peroxisome proliferator activated receptors (PPARs) and their effects on lipid metabolism and adipocyte differentiation," Biochem. Biophys. Acta. 1302: 93-109 (1996) | | | | |
| | FX | Sher et al., "cDNA cloning, chromosomal mapping, and functional characterization of the human peroxisome proliferators activated receptor," Biochemistry 32:5598-5604 (1993) | | | | |
| | FY | Shimomura et al., "Cholesterol feeding reduces nuclear forms of sterol regulatory element binding proteins in hamster liver," Proc. Natl. Acad. Sci. USA 94:12345-12359 (1997) | | | | |
| | FZ | Shuman, R.M., "Production of transge | enic birds," Experientia 47: 897- | 905 (1991) | | |
| | GA | Simons et al., "Gene transfer into sheep," Bio/Technology 6:179-183 (1988) | | | | |
| | GB | Smith et al., "Multiple Sterol Regulatory Elements in Promoter for Hamster 3-Hydroxy-3-methylglutaryl-conenzyme A synthase," J. Biol. Chem. 263:18480-18487 (1988) | | | | |
| | GC | Spiegelman, B.M. and J.S. Flier, "Adipogenesis and obesity rounding out the big picture," Cell 87: 377-389 (1996) | | | | |
| | GD | Stenson et al., "Dietary Supplementation with fish oil in ulcerative colitis," Annals of Internal Medicine 116:609-614 (1992) | | | | |
| | GE | Stratford Perricaudet et al., "Widespread long-term gene transfer to mouse skeletal muscles and heart," J. Clin. Invest. 90:626-630 (1992) | | | | |
| | GF | Tontonoz et al., "PPARy Promotes Monocyte/Macrophage Differentiation and Uptake of Oxidized LDL," Cell 93(2):241-252 (1988) | | | | |
| | GG | Tontonoz et al., "Stimulation of Adipogenesis in Fibroblasts by PPARy2, a Lipid-Activated Transcription Factor," Cell 79: 1147-1156 (1994) | | | | |
| | GH | Tontonoz et al., "PPARγ2 regulates adipose expression of the phosphoenolpyruvate carboxykinase gene," Mol. Cell. Biol. 15: 351-357 (1995) | | | | |
| | GI | Tontonoz et al., "mPPARy2: tissue-specific regulator of an adipocyte enhancer," Genes & Developement. 8(10): 1224-1234 (1994) | | | | |
| | GJ | Tontonoz et al., "ADD1: a Novel Helix-Loop-Helix Transcription Factor Associated with Adipocyte Determination and Differentiation," Mol. Cell. Biol. 13: 4753-4759 (1993) | | | | |
| | GK | Tugwood et al., "The mouse peroxisome proliferators activated receptor recognizes a response element in the 5' flanking sequence of the rat acyl CoA oxidase gene," EMBO J. 11: 433-439 (1992) | | | | |
| | GL | Vidal et al., "The expression of ob gene is not acutely regulated by insulin and fasting in human abdominal subcutaneous adipose tissue," J. Clin. Invest. 98: 251-255 (1996) | | | | |
| | GM | Vu-Dac et al., "Fibrates increases human apolipoprotein A-II expression through activation of the peroxisome proliferators-activated receptor," J. Clin. Invest. 96: 741-750 (1995) | | | | |
| | GN | Wang et al., "SREBP-1, a membrane-bound transcription factor released by sterol-regulated proteolysis," Cell 77:53-62 (1994) | | | | |
| - | GO | Willson et al., "The Structure-Activity Relationship between peroxisome proliferators-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones," J. Med. Chem. 39: | | | | |
| | 665-668 (1996) | | | | | |
| | Wu et al., "Receptor-mediated gene delivery in vivo, partial correction of genetic analbuminemia in nagase rats" Journal of Biological Chemistry 266:14338-14342 (1991) | | | | | |
| Examiner Signature | | | Date Considered (| 1/9/05 | | |

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

| | | U.S. Department of Commerce Patent and Trademark Office | Attorney's Docket No. 18202-033US1/1051US | Application No. 09/463,542 OIPE | | |
|--|--------------|---|---|-----------------------------------|--|--|
| List of Patents and Publications for Applicant's Information Disclosure Statement | | Applicant Johan Auwerx et al. | JUN 2 0 2005 | | | |
| (37 CFR §1.98(b)) | | | Filing Date December 11, 2002 | Group Art Unit 1636 (U)3 RADEMARK | | |
| Other Documents (include Author, Title, Date, and Place of Publication) | | | | | | |
| Examiner Initial | Desig. ID | | Document | | | |
| WΜ | GQ | Wu et al., "Induction of peroxisome proliferator-activated receptor γ during the conversion of 3T3 fibroblasts into adipocytes is mediated by C/EBPβ, C/EBPδ, and glucocorticoids," Mol.Cell. Biol. 16(8): 4128-4136 (1996) | | | | |
| | GR | Wu et al., "Conditional ectopic expression of C/EBPβ in NIH-3T3 cells induces PPARγ and stimulates adipogenesis," Genes & Developement 9: 2350–2363 (1995) | | | | |
| | GS | Xue et al., "Distinct Stages in Adipogenesis Revealed by Retinoid Inhibition of Differentiation after Induction of PPARγ," Mol. Cell. Biol. 16: 1567-1575 (1996) | | | | |
| | GT | Yang et al., "In vivo and in vitro gene transfer to mammalian somatic cells by particle bombardment," Proc. Natl. Acad. Sci. U.S.A. 87:9568-9572 (1990) | | | | |
| | GU | Yanofsy, C., "Attenuation in the control of expression of bacterial operons," Nature 289:751-758 (1981). | | | | |
| | · GV | Yeh et al., "Cascade regulation of terminal adipocyte differentiation by three members of the C/EBP family of leucine zipper proteins," Genes & Development 9: 168-181 (1995) | | | | |
| | GW | Yokoyama et al., "SREBP-1, a Basic-Helix-Loop-Helix-Leucine Zipper Protein that Controls Transcription of the Low Density Lipoprotein Receptor Gene," Cell 75:187-197 (1993) | | | | |
| WW | GX | Zhu et al., "Structural organization of mouse peroxisome proliferators-activated receptor y (mPPARy) gene: Alternative promoter use and different splicing yield two mPPARy isoforms," | | | | |

Examiner Signature Date Considered EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.